Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
2
×
boston blog main
boston top stories
kaleido biosciences
2
×
life sciences
national blog main
national top stories
new york blog main
san francisco blog main
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
azacitidine
beta-thalassemia
bluebird bio
clinical trials
dacogen
deals
decitabine
dna
duchenne muscular dystrophy
dyne therapeutics
epigenetics
epizyme
facioscapulohumeral muscular dystrophy
farydak
flagship pioneering
fulcrum therapeutics
gene therapy
insulated genomic domains
joshua brumm
mahesh karande
muscular dystrophy
myotonic dystrophy type 1
new york top stories
omega therapeutics
panobinostat
rare disease drugs
What
medicines
therapeutics
2
×
ago
aims
approach
based
biotech
biotechs
called
considering
data
debuts
developing
diseases
drug
drugs
dyne
early
epigenetic
epigenetics
expected
experimental
eyes
field
flagship’s
genetic
having
humans
ipo
ipos
long
morning
muscle
new
omega
rare
reach
research
startup
step
Language
unset
Current search:
therapeutics
×
boston
×
" kaleido biosciences "
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
